135 related articles for article (PubMed ID: 36233406)
1. Lesion-to-Liver SUVmax Ratio to Improve the Prognostic Value of the End of Treatment PET/CT in Diffuse Large B-Cell Lymphoma.
Ferrari C; Pisani AR; Masi T; Santo G; Mammucci P; Rubini D; Sardaro A; Rubini G
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233406
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of therapeutic effect and prognostic value of
Zhao W; Wu X; Huang S; Wang H; Fu H
EJNMMI Res; 2024 Feb; 14(1):20. PubMed ID: 38372908
[TBL] [Abstract][Full Text] [Related]
4. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
Toledano MN; Vera P; Tilly H; Jardin F; Becker S
PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment].
Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636
[No Abstract] [Full Text] [Related]
6. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
[TBL] [Abstract][Full Text] [Related]
7. Dynamic evaluation of the prognostic value of
Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Accuracy and Risk Stratification in End of Therapy
Mo YW; Xiao ZZ; Wei Y; Li XL; Zhang X; Fan W
Front Oncol; 2021; 11():625436. PubMed ID: 33968725
[TBL] [Abstract][Full Text] [Related]
9. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV
Annunziata S; Cuccaro A; Tisi MC; Hohaus S; Rufini V
Ann Nucl Med; 2018 Jun; 32(5):372-377. PubMed ID: 29464479
[TBL] [Abstract][Full Text] [Related]
11. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET).
Annunziata S; Cuccaro A; Calcagni ML; Hohaus S; Giordano A; Rufini V
Ann Nucl Med; 2016 Oct; 30(8):588-92. PubMed ID: 27246952
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma.
Chen X; Zhao S; Wang H; Fu C; Tian R; Zou L
Quant Imaging Med Surg; 2021 Apr; 11(4):1220-1233. PubMed ID: 33816162
[TBL] [Abstract][Full Text] [Related]
13. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
[TBL] [Abstract][Full Text] [Related]
14. Prognostic analysis of interim
Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
[TBL] [Abstract][Full Text] [Related]
15. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Pretreatment 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
[No Abstract] [Full Text] [Related]
17. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
[TBL] [Abstract][Full Text] [Related]
18. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
[TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma.
Vaxman I; Bernstine H; Kleinstern G; Hendin N; Shimony S; Domachevsky L; Gurion R; Groshar D; Raanani P; Gafter-Gvili A
Hematol Oncol; 2019 Apr; 37(2):168-175. PubMed ID: 30734341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
